Q32 Bio Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
830 WINTER STREET, WALTHAM, MA, 02451
Mailing Address
830 WINTER STREET, WALTHAM, MA, 02451
Phone
781-999-0232
Fiscal Year End
1231
EIN
473468154
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 424B5 Prospectus supplement | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 12, 2026 | View on SEC |
| 10-K Annual financial report | March 10, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
Annual Reports
10-K
March 10, 2026
- Advancing lead product bempikibart (ADX-914) for multiple autoimmune indications.
- Implemented strategic restructuring, including workforce reduction, to extend cash runway and focus on core programs.
Insider Trading
SELL
3 insiders
5 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.